Title (COG AALL1131) A Phase III Randomized Trial for Newly Diagnosed High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
Principal Investigator Martin Brecher, MD
Study Number 206911
Summary To define optimal intrathecal agents for use with effective chemotherapy with minimal increase in toxicity nad/or burden of therapy for children with HR-ALL. Patient will be randomized to post-induction therapy with a modified BFM backbone that includes a single Interim Maintenance (IM) phase with high dose methotrexate and a single Delayed Intensification (DI) phase with either intrathecal methotrexate only.
Eligibility Please see ClinicalTrials.gov link